Skip to main content
OpenTrials
Completed

NCT Number: NCT05368909

Clinical Study to Assess a Dietary Supplement on Sleep Health and Quality

The primary objective of this study is to evaluate the effects of a proprietary oral supplement on the sleep health and quality of people with sleep problems. It is a double-blinded placebo-controlled crossover clinical study.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

4Life Research

Sandy City, Utah, 84070, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Non-smokers
  • Judged by the Investigator to be in general good health on the basis of medical history
  • Willing to wash out of all dietary supplements, essential oils, and non-prescription sleep aids or Rx sleep aids for the duration of the study
  • Insomnia Severity Index score of ≥ 8
  • Must agree to maintain the same eating, exercise, and sleep arrangements for the whole duration of the study

Exclusion criteria

  • Pregnant and/or lactating women
  • Known allergy or adverse reaction to ingredients in the product: Tri Factor (bovine colostrum and egg yolk extracts), Ashwagandha root extract, Lavender, Pyridoxal-5-Phosphate, Melatonin, gamma aminobutyric acid (GABA) or Magnesium
  • Prescription sedative or psychoactive (including anti-depressant) medication use
  • Diagnosis of a sleep disorder (e.g., sleep apnea, periodic limb movement disorder, etc.) or high clinical probability of another sleep disorder based on sleep history
  • A clinically unstable medical condition as defined by a new diagnosis or change in medical management in the previous 4 months (e.g., myocardial infarction, congestive heart failure, Cheyne-Stokes breathing, unstable angina, thyroid disease, depression or psychosis, ventricular arrhythmias, cirrhosis, surgery, or recently diagnosed cancer)
  • Routine consumption of more than 2 alcoholic beverages per day or consumption of caffeine past 2 PM for the duration of the study
  • Illicit drug use
  • Use of prescription stimulants (modafinil, dextroamphetamine, etc.)
  • Use of prescription medications known to affect sleep (antidepressants, anti-anxiety, opioids, alpha-blockers, beta-blockers, corticosteroids, ACE inhibitors, angiotensin II-receptor blockers, cholinesterase inhibitors, allergy medication, asthma medication, glucosamine and chondroitin, statins, anti-smoking or thyroid medication, muscle relaxants, anticonvulsants)
  • Unable to perform tests due to inability to communicate verbally, inability to write and read in English; less than a 10th grade reading level; visual, hearing or upper extremity motor deficit
  • Night shift workers in situations or occupations where they regularly experience jet lag, or have irregular work schedules by history over the last 6 months
  • Unwilling to consume or unable to swallow capsules/tablets
  • Previous exposure to this product in earlier testing phases

Treatment and study plan

Sleep Supplement

Dietary Supplement

Proprietary sleep formula containing Tri Factor, Ashwagandha root extract, Lavender, Pyridoxal-5-Phosphate, Melatonin, gamma aminobutyric acid (GABA) and Magnesium.

Placebo

Dietary Supplement

Placebo product

Primary outcomes

  1. Saliva Melatonin level changes

    Time frame: 6 weeks

    Samples taken before bedtime at night and 2 hours after wakeup the next morning. A total of 8 samples were taken for each subject: (2) right after first washout, (2) right after Arm 1, (2) right after the second washout, (2) right after Arm 2.

  2. Insomnia Severity Index Score

    Time frame: 6 weeks

    A scale used to measure the severity of insomnia. Total score categories:

    0-7 = No clinically significant insomnia 8-14 = Subthreshold insomnia 15-21 = Clinical insomnia (moderate severity) 22-28 = Clinical insomnia (severe)

Secondary outcomes

  1. Sleep Onset Latency

    Time frame: 6 weeks

    Sleep latency, or sleep onset latency, is the time it takes a person to fall asleep after turning the lights out.

  2. Total Sleep Time

    Time frame: 6 weeks

    Total time a person spends asleep over a given night

  3. Sleep Efficiency

    Time frame: 6 weeks

    Sleep efficiency is typically referring to the percentage of time a person spends asleep at night. To calculate this, you take a ratio of the total amount of time a person was asleep on a given night divided by the total amount of time they spent in bed, then multiply that by 100 to create a percentage.

  4. Leeds Sleep Evaluation Questionnaire (LSEQ) Score

    Time frame: 6 weeks

    A 10-item, subjective, self-report measure, the LSEQ was designed to assess changes in sleep quality over the course of a psychopharmacological treatment intervention. The scale evaluates four domains: ease of initiating sleep, quality of sleep, ease of waking, and behavior following wakefulness. Total LSEQ Score ranges from 0 to 100, with 100 being the worst sleep quality and health overall.

Sponsors and collaborators

Lead sponsor

4Life Research, LLC

Industry

Registry information

Official study title

Assessment of the Effects of a Dietary Supplement on the Sleep Health and Sleep Quality of People With Sleep Problems: A Randomized, Double-blind, Placebo-controlled, Crossover Design Study

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
May 10, 2022
Registry last updated
Jul 12, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.